The role of sulfonylureas in the treatment of type 2 diabetes

Tomlinson, Brian; Patil, NG; Fok, Manson; Chan, Paul

doi:10.1080/14656566.2021.1999413

Cited by 26 publications

(18 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With availability of newer GLDs with low risk of hypoglycaemia, the position of SUs is being re‐evaluated. 46 International guidelines are often based on evidence from RCTs with good internal validity, although real‐world data can provide valuable insights for external validity. 24 Although over 50% of patients with diabetes come from the Asia‐Pacific region, 1 Asians are generally under‐represented in RCTs.…”

Section: Discussionmentioning

confidence: 99%

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Lim

Lau

Cheung

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims To explore the patterns of use of oral glucose‐lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods We conducted a cross‐sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon‐like peptide‐1 receptor agonists were excluded. Results Amongst 62 512 patients (mean ± standard deviation age: 57.3 ± 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU‐based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase‐4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non‐gliclazide SU users (odds ratio [OR] 1.09, 95% CI 1.02‐1.17), with less frequent self‐reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72‐0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). Conclusion In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Lim

Lau

Cheung

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Regarding the potential use in clinical trials, glyburide, also called glibenclamide, is an oral antidiabetic drug which is widely used in the treatment of type II diabetes ( 60 ). This would facilitate clinical trials using glyburide as potential treatment option for aortic aneurysm if further preclinical studies confirm its therapeutic value.…”

Section: Discussionmentioning

confidence: 99%

Inflammasome Targeted Therapy as Novel Treatment Option for Aortic Aneurysms and Dissections: A Systematic Review of the Preclinical Evidence

Wortmann

Klotz

Kalkum

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Both aortic aneurysm and dissection are life threatening pathologies. In the lack of a conservative medical treatment, the only therapy consists of modifying cardiovascular risk factors and either surgical or endovascular treatment. Like many other cardiovascular diseases, in particular atherosclerosis, aortic aneurysm and dissection have a strong inflammatory phenotype. Inflammasomes are part of the innate immune system. Upon stimulation they form multi protein complexes resulting mainly in activation of interleukin-1β and other cytokines. Considering the gathering evidence, that inflammasomes are decisively involved in the emergence and progression of aortic diseases, inflammasome targeted therapy provides a promising new treatment approach. A systematic review following the PRISMA guidelines on the current preclinical data regarding the potential role of inflammasome targeted drug therapy as novel treatment option for aortic aneurysms and dissections was performed. Included were all rodent models of aortic disease (aortic aneurysm and dissection) evaluating a drug therapy with direct or indirect inhibition of inflammasomes and a suitable control group with the use of the same aortic model without the inflammasome targeted therapy. Primary and secondary outcomes were incidence of aortic disease, aortic rupture, aortic related death, and the maximum aortic diameter. The literature search of MEDLINE (via PubMed), the Web of Science, EMBASE and the Cochrane Central Registry of Registered Trials (CENTRAL) resulted in 8,137 hits. Of these, four studies met the inclusion criteria and were therefore eligible for data analysis. In all of them, targeting of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome effectively reduced the incidence of aortic disease and aortic rupture, and additionally reduced destruction of the aortic wall. Treatment strategies aiming at other inflammasomes could not be identified. In conclusion, inflammasome targeted therapies, more precisely targeting the NLRP3 inflammasome, have shown promising results in rodent models and deserve further investigation in preclinical research to potentially translate them into clinical research for the treatment of human patients with aortic disease. Regarding other inflammasomes, more preclinical research is needed to investigate their role in the pathophysiology of aortic disease.Protocol Registration: PROSPERO 2021 CRD42021279893, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021279893

show abstract

“…Metformin, the first‐line glucose‐lowering drug, was first synthesized in 1922, but it was not until 2022 that metformin was confirmed to exert a hypoglycemic effect by activating the presenilin enhancer 2 (PEN2)‐mediated AMPK protein 15,16 signaling pathway. Akin to metformin, sulfonylureas (SUs) were found to have hypoglycemic effects accidentally in 1942, but it was until 1979 when researchers truly found the underlying mechanism, by which acting on β cells to stimulate insulin secretion through closing K + channels and activating Ca 2+ signal 17 . In the latest years, novel hypoglycemic drugs, such as GLP‐1 and sodium‐glucose cotransporter 2 (SGLT2) inhibitor, are effective in reducing fasting blood glucose 18 and preventing the reabsorption of urine glucose, 19 regardless of their unspecified mechanisms.…”

Section: History Of T2dm and Signaling Pathwaysmentioning

confidence: 99%

Signaling pathways and intervention for therapy of type 2 diabetes mellitus

Cao

Tian

Zhang

et al. 2023

MedComm

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) represents one of the fastest growing epidemic metabolic disorders worldwide and is a strong contributor for a broad range of comorbidities, including vascular, visual, neurological, kidney, and liver diseases. Moreover, recent data suggest a mutual interplay between T2DM and Corona Virus Disease 2019 (COVID‐19). T2DM is characterized by insulin resistance (IR) and pancreatic β cell dysfunction. Pioneering discoveries throughout the past few decades have established notable links between signaling pathways and T2DM pathogenesis and therapy. Importantly, a number of signaling pathways substantially control the advancement of core pathological changes in T2DM, including IR and β cell dysfunction, as well as additional pathogenic disturbances. Accordingly, an improved understanding of these signaling pathways sheds light on tractable targets and strategies for developing and repurposing critical therapies to treat T2DM and its complications. In this review, we provide a brief overview of the history of T2DM and signaling pathways, and offer a systematic update on the role and mechanism of key signaling pathways underlying the onset, development, and progression of T2DM. In this content, we also summarize current therapeutic drugs/agents associated with signaling pathways for the treatment of T2DM and its complications, and discuss some implications and directions to the future of this field.

show abstract

The role of sulfonylureas in the treatment of type 2 diabetes

Cited by 26 publications

References 143 publications

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Inflammasome Targeted Therapy as Novel Treatment Option for Aortic Aneurysms and Dissections: A Systematic Review of the Preclinical Evidence

Signaling pathways and intervention for therapy of type 2 diabetes mellitus

Contact Info

Product

Resources

About